Abstract

Background: REDES is the largest European real-world study on the effectiveness and safety of mepolizumab in Severe Asthma (SA) (n=318). This post hoc analysis assessed the influence of smoking on mepolizumab effectiveness.

Methods: REDES is a retrospective, observational study in patients with SA treated with mepolizumab 100mg SC every 4 weeks in Spain. We evaluated the baseline demographic and clinical outcomes over 1 year of treatment in the patients classified as never-smokers, ex-smokers and current smokers included in the study.

Results: 198 never smokers, 106 ex-smokers (>6 months without smoking) and 4 current smokers were included. The table shows their baseline features. In the non-smoker, ex-smoker and current smoker patients, respectively, their exacerbation reduction was 78%, 76% and 72%, their ACT improved 6.41, 7.28 and 1.5 points, their OCS dose decreased 62%, 56% and 100%, and the eosinophils were reduced by 85%, 76% and 64%.

Conclusions: Despite the limited number of current smokers, results from this post hoc analysis of REDES suggest that smoking status does not influence mepolizumab effectiveness of patients with severe asthma.

Funding: GSK (GSK ID 213172).